XOLAIR
Biological
Novartis Pharmaceuticals Corporation
Total Payments
$5.2M
Transactions
71,843
Doctors
11,631
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $255,347 | 9,936 | 3,359 |
| 2023 | $271,885 | 10,228 | 3,787 |
| 2022 | $236,205 | 8,408 | 3,246 |
| 2021 | $284,028 | 6,187 | 2,757 |
| 2020 | $466,596 | 4,023 | 2,199 |
| 2019 | $1.2M | 11,852 | 4,003 |
| 2018 | $1.3M | 11,163 | 4,116 |
| 2017 | $1.2M | 10,046 | 4,246 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.1M | 194 | 40.0% |
| Food and Beverage | $1.4M | 70,389 | 26.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $878,049 | 324 | 17.0% |
| Consulting Fee | $571,484 | 156 | 11.1% |
| Travel and Lodging | $179,746 | 643 | 3.5% |
| Space rental or facility fees (teaching hospital only) | $80,640 | 50 | 1.6% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $33,110 | 16 | 0.6% |
| Education | $652.81 | 71 | 0.0% |
Payments by Type
General
$3.1M
71,649 transactions
Research
$2.1M
194 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A THREE MONTH SINGLE CENTER STUDY TO IDENTIFY BIOMARKERS AND OR MECHANISM OF RESPOND TO XOLAIR OMALIZUMAB 300MG SUBCUTANEOUSLY MONTHLY FOR 3 DOSES THERAPY IN PATIENTS WITH CHRONIC IDIOPATHIC URTICARIA PLASMA EXOSOMAL MIRNSS AS PREDICTORS OF RESPONSE AND OR DISEASE SEVERITY AND BASOPHIL TRANSCRIPTOME ANALYSIS TO DETERMINE MECHANISM OF RESPONSE | Novartis Pharmaceuticals Corporation | $317,544 | 0 |
| GENERAL PROGRAM SUPPORT FOR IGE0255A | Novartis Pharmaceuticals Corporation | $316,291 | 0 |
| A THREE MONTH SINGLE CENTER STUDY TO IDENTIFY BIOMARKERS AND OR MECHANISM OF RESPOND TO XOLAIR OMALIZUMAB 300MG SUBCUTANEOUSLY MONTHLY FOR 3 DOSES THERAPY IN PATIENTS WITH CHRONIC IDIOPATHIC URTICARIA PLASMA EXOSOMAL MIRNSS AS PREDICTORS OF RESPONSE AND O | Novartis Pharmaceuticals Corporation | $295,824 | 0 |
| DEVELOPMENT OF NOVEL HOSPITAL INITIATED CARE BUNDLE IN ADULTS HOSPITALIZED FOR ASTHMA EXACERBATION THE 41TH MULTICENTER AIRWAY RESEARCH COLLABORATION MARC 41 STUDY | Novartis Pharmaceuticals Corporation | $203,908 | 0 |
| ASSESSING ELIGIBILITY FOR XOLAIR OMALIZUMAB IN THE ASTHMA COPD OVERLAP SYNDROME | Novartis Pharmaceuticals Corporation | $170,000 | 0 |
| ROLE OF IGE BEARING CELLS IN CHRONIC IDIOPATHIC URTICARIA | Novartis Pharmaceuticals Corporation | $158,591 | 0 |
| EXPLORATORY TRIAL OF XOLAIR OMALIZUMAB FOR IDIOPATHIC ANGIOEDEMA | Novartis Pharmaceuticals Corporation | $110,555 | 0 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $107,027 | 17 |
| IN SITU ANALYSIS OF SPUTUM DERIVED CELLULAR TARGETS AFTER XOLAIR | Novartis Pharmaceuticals Corporation | $100,236 | 0 |
| AN EVALUATION OF TREATMENT WITH XOLAIROMALIZUMAB TO IMPROVE THE ASTHMATIC RESPONSE TO AN EXPERIMENTAL INFECTION WITH RHINOVIRUS | Novartis Pharmaceuticals Corporation | $58,542 | 0 |
| OMALIZUMAB TREATMENT PATTERNS IN THE U.S. MEDICARE POPULATION | NOVARTIS PHARMACEUTICALS CORPORATION | $45,342 | 0 |
| XOLAIROMALIZUMAB ADMINISTRATION IN PATIENTS WITH IGE MEDIATED ADVERSE DRUG REACTIONS PRIOR TO DRUG DESENSITIZATIONS 3RD PARTY IIRP STUDY PROTOCOL WRITTEN BY PI DR HONG AT BRIGHAM WOMANS HOSPITAL | Novartis Pharmaceuticals Corporation | $40,319 | 0 |
| Omalizumab Before Onset of Exacerbations URI-induc. asthma exacerbation | Novartis Pharmaceuticals Corporation | $40,008 | 0 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $32,737 | 7 |
| OUTCOMES RESEARCH | Novartis Pharmaceuticals Corporation | $18,515 | 2 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH XOLAIR RESEARCH | Novartis Pharmaceuticals Corporation | $15,750 | 3 |
| Publication support research related | Novartis Pharma AG | $9,346 | 1 |
| OMALIZUMAB BEFORE ONSET OF EXACERBATIONS URI-INDUC. ASTHMA EXACERBATION | Novartis Pharmaceuticals Corporation | $8,380 | 0 |
| A 26 WEEK RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED MULTI CENTER STUDY TO EVALUATE THE EFFECT OF OMALIZUMAB ON MARKERS OF ASTHMA IMPAIRMENT IN PATIENTS WITH PERSISTENT ALLERGIC ASTHMA | Novartis Pharmaceuticals Corporation | $6,528 | 0 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $6,428 | 2 |
Top Doctors Receiving Payments for XOLAIR
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $2.0M | 126 |
| , MD | Allergy & Immunology | Upland, PA | $164,634 | 229 |
| , MD | Allergy & Immunology | Fitchburg, WI | $156,513 | 149 |
| , MD | Allergy & Immunology | Elmhurst, IL | $84,621 | 137 |
| , MD | Pediatrics | Saint Louis, MO | $55,058 | 57 |
| , M.D | Internal Medicine | Gardner, MA | $51,863 | 65 |
| , D.O | Allergy | Lakewood, WA | $47,883 | 52 |
| Mayank Shukla | Sleep Medicine | Brooklyn, NY | $44,675 | 69 |
| , M.D | Allergy & Immunology | Tampa, FL | $39,221 | 47 |
| , D.O | Allergy & Immunology | Colorado Springs, CO | $37,166 | 88 |
| , MD | Allergy & Immunology | Benbrook, TX | $37,135 | 26 |
| , DO | Allergy & Immunology | Northampton, MA | $33,208 | 106 |
| , MD | Allergy & Immunology | Rockville Centre, NY | $31,785 | 47 |
| , M.D | Pediatric Allergy/Immunology | Norfolk, VA | $30,271 | 32 |
| , MD | Pediatrics | San Antonio, TX | $29,254 | 74 |
| , MD | Allergy & Immunology | North Charleston, SC | $29,155 | 64 |
| , M.D | Allergy & Immunology | Louisville, KY | $26,636 | 37 |
| , MD | Allergy | Riverdale, NJ | $23,706 | 44 |
| , M.D | Allergy | Baltimore, MD | $22,701 | 78 |
| , MD | Internal Medicine | Cincinnati, OH | $22,562 | 24 |
| , MD | Pulmonary Disease | Newark, DE | $22,464 | 35 |
| , M.D | Internal Medicine | Cincinnati, OH | $22,064 | 34 |
| , MD | Allergy & Immunology | Gilbert, AZ | $19,564 | 23 |
| , MD | Pediatric Pulmonology | Norcross, GA | $18,199 | 27 |
| , MD | Clinical & Laboratory Immunology | Los Angeles, CA | $18,123 | 35 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $4.7M
- NOVARTIS PHARMACEUTICALS CORPORATION $401,255
- Novartis Pharma AG $16,416
Product Information
- Type Biological
- Total Payments $5.2M
- Total Doctors 11,631
- Transactions 71,843
About XOLAIR
XOLAIR is a biological associated with $5.2M in payments to 11,631 healthcare providers, recorded across 71,843 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2024. In 2024, $255,347 was paid across 9,936 transactions to 3,359 doctors.
The most common payment nature for XOLAIR is "Unspecified" ($2.1M, 40.0% of total).
XOLAIR is associated with 20 research studies, including "A THREE MONTH SINGLE CENTER STUDY TO IDENTIFY BIOMARKERS AND OR MECHANISM OF RESPOND TO XOLAIR OMALIZUMAB 300MG SUBCUTANEOUSLY MONTHLY FOR 3 DOSES THERAPY IN PATIENTS WITH CHRONIC IDIOPATHIC URTICARIA PLASMA EXOSOMAL MIRNSS AS PREDICTORS OF RESPONSE AND OR DISEASE SEVERITY AND BASOPHIL TRANSCRIPTOME ANALYSIS TO DETERMINE MECHANISM OF RESPONSE" ($317,544).